Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Neuroblastoma, a childhood cancer, often exhibits hampered wild-type p53 tumor suppressor activity due to increased MDM2 activity.
• Selective MDM2 antagonists represent a potential therapeutic avenue, but monotherapy often yields limited clinical responses.

Purpose of the Study:

• To identify small molecule drugs that synergize with idasanutlin (a selective MDM2 antagonist).
• To evaluate the combination of idasanutlin with other targeted therapies for neuroblastoma treatment.

Main Methods:

• Screening of 15 targeted drugs in combination with idasanutlin across three p53 wild-type neuroblastoma cell lines.
• Assessment of synergistic effects, apoptosis induction (caspase-3/7, cleaved PARP), and in vivo tumor growth in orthotopic xenograft models.

Main Results:

• Venetoclax (ABT-199), a BCL2 inhibitor, was identified as a synergistic partner for idasanutlin.
• The venetoclax/idasanutlin combination demonstrated consistent synergy across diverse neuroblastoma cell lines, including those with high MCL1 expression.
• Combination treatment significantly reduced tumor weights in mice compared to monotherapy, with enhanced apoptosis induction.

Conclusions:

• Dual targeting of BCL2 and MDM2 with venetoclax and idasanutlin is a highly synergistic strategy in neuroblastoma.
• This combination therapy effectively induces apoptosis and suppresses tumor growth.
• Further clinical evaluation of dual BCL2/MDM2 targeting is strongly supported for neuroblastoma treatment.